Drugs / HyperAcute® Melanoma vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00746746 | Jun 2008 → Jun 2010 | melanoma | Ochsner Health System | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HyperAcute Melanoma vaccine | “The purpose of this study is to determine the safety of giving subjects with advanced, recurrent or refractory melanoma the HyperAcute® Melanoma vaccine” NCT00746746 ↗ |
| Known as | HyperAcute-Melanoma | “The study vaccine (HyperAcute®-Melanoma) is made from three types of human melanoma cell lines” NCT00746746 ↗ |
| Modality | Vaccine | “HyperAcute® Melanoma vaccine” NCT00746746 ↗ |